

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CStone Pharmaceuticals
基石藥業

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON MARCH 7, 2023

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) of CStone Pharmaceuticals (the “**Company**”) dated February 15, 2023. The board (“**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that all the resolutions (the “**Resolutions**”) set out in the EGM Notice were duly passed by the shareholders of the Company as ordinary resolutions by way of poll at the extraordinary general meeting of the Company held on March 7, 2023 (the “**EGM**”). Capitalised terms contained in the circular dated February 15, 2023 issued by the Company shall have the same meanings when used herein unless otherwise specified.

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
1.	To consider and approve the proposed amendments to the Post-IPO ESOP	400,186,811 (84.0592%)	75,890,354 (15.9408%)	476,077,165 (100.0000%)
2.	To consider and approve the proposed amendments to the Post-IPO RSU Scheme	400,186,811 (84.0592%)	75,890,354 (15.9408%)	476,077,165 (100.0000%)
3.	To consider and approve the Scheme Mandate Limit	400,186,811 (84.0592%)	75,890,354 (15.9408%)	476,077,165 (100.0000%)
4.	To consider and approve the Service Provider Sublimit	400,186,811 (84.0592%)	75,890,354 (15.9408%)	476,077,165 (100.0000%)
5.	To re-grant Options to Dr. Yang, an Existing Grantee, under the Post-IPO ESOP to subscribe for an aggregate of 4,340,000 Shares	406,693,945 (84.3762%)	75,306,997 (15.6238%)	482,000,942 (100.0000%)
6.	To grant Options to Dr. Yang under the Post-IPO ESOP to subscribe for an aggregate of 28,000,000 Shares	406,693,945 (84.3762%)	75,306,997 (15.6238%)	482,000,942 (100.0000%)

Notes:

1. As more than 50% of the votes were cast in favour of each of the Resolutions, all the Resolutions proposed at the EGM were duly passed as ordinary resolutions.
2. The full text of the Resolutions is set out in the EGM Notice.
3. Dr. Yang and his associates, directly and indirectly, holding an aggregate of 8,378,053 Shares of the Company, representing approximately 0.65% of the total issued share capital of the Company as at the date of the EGM, abstained from voting on the Resolutions No. 5 and No. 6 proposed at the EGM. The total Shares entitling Shareholders to attend and vote on Resolutions No. 5 and No. 6 proposed at the EGM were 1,275,465,959 Shares, and the total Shares entitling Shareholders to attend and vote on Resolutions other than Resolutions No. 5 and No. 6 proposed at the EGM were 1,283,844,012 Shares.

To the best of the knowledge, information and belief of the Board, and having made all reasonable enquiries:

- (i) there were no Shareholders who were entitled to attend the EGM but was required to abstain from voting in favor of the Resolutions proposed at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”);
 - (ii) none of the Shareholders was required under the Listing Rules to abstain from voting on any of the Resolutions proposed at the EGM, except that Dr. Yang and his associates are required to abstain from voting on Resolutions No. 5 and No. 6; and
 - (iii) save as disclosed above, there was no restriction on any Shareholders to cast votes on any of the Resolutions proposed at the EGM and none of the Shareholders have stated their intention in the circular of the Company dated February 15, 2023 to vote against or to abstain from voting on any of the Resolutions at the EGM.
4. Computershare Hong Kong Investor Services Limited, the Company’s Hong Kong share registrar, was appointed as the scrutineer at the EGM for the purpose of vote-taking in respect of the Resolutions.
 5. The following Directors attended the EGM either in person or by electronic means: Dr. Jianxin Yang, Dr. Wei Li, Mr. Edward Hu, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun. Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Dr. Paul Herbert Chew were unable to attend the EGM due to other business commitment.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Hong Kong, March 7, 2023

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive Director, Dr. Jianxin Yang as executive Director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.